Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD
Business Of Biotech
00:00
What Is an Ideal Partnership Scenario?
I feel that we are in a very good position from that perspective, because we've got multiple things in our pipeline that are partnerable. And given how differentiated our ADCs could be, I think a lot of big pharma are interested in that and that type of ADCs. We have quite a bit of research capabilities where we can help other companies build ADCs, fix their ADCs problems, or come up with new targets with 480Cs. So all of these are potential partnering activities, along with partnering just the linker or the warhead.
Transcript
Play full episode
